期刊文献+
共找到5篇文章
< 1 >
每页显示 20 50 100
Effects of Maixuekang Capsules Combined with Edaravone on Serum MMP-9, S-100β Protein Levels and Neurological Functions in Patients with Hemorrhagic Cerebral Infarction 被引量:2
1
作者 Zhang Jianqiang Jiao Yongping 《World Journal of Integrated Traditional and Western Medicine》 2019年第1期34-39,共6页
OBJECTIVE: To investigate the effects of Maixuekang Capsules combined with edaravone on serum matrix metalloproteinase-9(MMP-9), S-100β protein levels and neurological functions in patients with hemorrhagic cerebral ... OBJECTIVE: To investigate the effects of Maixuekang Capsules combined with edaravone on serum matrix metalloproteinase-9(MMP-9), S-100β protein levels and neurological functions in patients with hemorrhagic cerebral infarction. METHOSDS: A total of 76 patients with hemorrhagic cerebral infarction treated in the First Affiliated Hospital of Henan University of Science and Technology from January 2017 to May 2018 were selected and were randomly divided into treatment group and control group, with 38 patients in each group. The control group was given edaravone, and the treatment group was given Maixuekang Capsules on the basis of the control group. The clinical efficacy, serum MMP-9 and S-100β protein levels, neurological function recovery, activity of daily living and incidence rate of adverse reactions were compared between the 2 groups. RESULTS: The total effective rate of the treatment group was 92.11%, which was higher than 71.05% of the control group(P < 0.05); the National Institutes of Health Stroke Scale(NIHSS) score in the 2 groups decreased(P < 0.05), and the Activity of Daily Living Scale(ADL) score increased(P < 0.05), the improvement of the above 2 scores in the treatment group were better than those in the control group(P < 0.05); the level of MMP-9 was gradually decreasing in the 2 groups, on the 7th day, 14 th day after treatment, and the levels of MMP-9 decreased significantly(P < 0.05), and the treatment group was lower than the control group at all time points(P < 0.05); on the 3rd day after treatment, the levels of S-100β protein in the 2 groups increased significantly(P < 0.05); on the 7th day, 14 th day after treatment, the levels of S-100β protein in the two groups decreased significantly(P < 0.05), and the treatment group was significantly lower than the control group(P < 0.05); there was no significant difference in incidence rate of adverse reactions between 7.89% in the control group and 5.26% in the treatment group(P > 0.05). CONCLUSION: The combination of Maixuekang Capsules and edaravone is effective in treating hemorrhagic cerebral infarction, and it can significantly improve neurological function defect and daily living ability, reduce serum MMP-9 and S-100β protein levels, and has higher safety. 展开更多
关键词 Maixuekang Capsules EDARAVONE HEMORRHAGIC cerebral infarction matrix metalloproteinase-9 S-100Β protein NEUROLOGICAL function
下载PDF
Analysis of correlation between carotid atherosclerotic plaques and serum hs-CRP, Apo-B, ox-LDL and MMP-9 levels in patients with atherosclerotic cerebral infarction
2
作者 Zi-Jun Yan Liang-Ming Zhang +6 位作者 Yan-Qing Chen Wen-Hao Xu Yue-Hui Zhang Yu-Ping Lan Xiao-Yan Yuan Guan-Li Xu Xing-Meng Xu 《Journal of Hainan Medical University》 2019年第22期32-36,共5页
ObjectiveTo analyze the correlation between the levels of serum hypersensitive c-reactive protein(hs-CRP),apolipoprotein-B(Apo-B),oxidized low-density lipoprotein(ox-LDL)and matrix metalloproteinase-9(MMP-9)and caroti... ObjectiveTo analyze the correlation between the levels of serum hypersensitive c-reactive protein(hs-CRP),apolipoprotein-B(Apo-B),oxidized low-density lipoprotein(ox-LDL)and matrix metalloproteinase-9(MMP-9)and carotid arteryplaque(CAP)in patients with atherosclerotic cerebral infarction(ASCI).Methods 125 patients with ASCI diagnosed in the Department of Neurology of Panzhihua Central Hospital from January 2018 to December 2018 were selected as the case group,and 125 healthy volunteers in the same period were selected as the control group.Serum levels of hs-CRP,Apo-B,ox-LDL and MMP-9 were compared between the two groups.Carotid ultrasound was performed in patients with ASCI.The correlation between serum levels of hs-CRP,Apo-B,ox-LDL and MMP-9 and the formation of CAP in patients with ASCI was analyzed by SPSS 23.0 statistics.Results Compared with the control group,the levels of serum hs-CRP,Apo-B,ox-LDL and MMP-9 increased significantly in the case group(P<0.01).The serum levels of hs-CRP,Apo-B,ox-LDL and MMP-9 in patients with CAP were significantly higher than those without CAP in the case group(P<0.01).Multivariate logistic regression analysis showed that serum levels of hs-CRP(OR=4.76,95%CI:2.35-9.18),Apo-B(OR=3.16,95%CI:1.59-7.32),ox-LDL(OR=1.48,95%CI:1.15-2.01)and MMP-9(OR=3.86,95%CI:1.63-9.14)were independent risk factors for CAP formation in patients with ASCI(P<0.05).ConclusionsThe contents of serumhs-CRP,Apo-B,ox-LDL and MMP-9 may reflect the serverity of inflammation and instability of carotid atherosclerotic plaque in ASCI patient.The levels of serum hs-CRP,Apo-B,ox-LDL and MMP-9 in patients with ASCI are significantly increased,which are closely related to the formation of CAP in patients with ASCI,so it can be used as important serum biomarkers for clinical diagnosis of ASCI and CAP formation. 展开更多
关键词 ATHEROSCLEROTIC cerebral infarction carotid arteryplaque HYPERSENSITIVE c-reactive protein APOLIPOprotein-B oxidized low-density LIPOprotein matrix metalloproteinase-9
下载PDF
血清基质金属蛋白酶-9——脑梗死预后的潜在临床标志物 被引量:17
3
作者 陈实 周志斌 +2 位作者 郭毅 唐冰杉 王晓萍 《国外医学(脑血管疾病分册)》 2004年第4期260-263,共4页
目的:研究血清基质金属蛋白酶-9(MMP-9)水平与缺血性卒中梗死体积和预后的关系,并探讨其潜在的机制。方法:对纳入研究的124例缺血性卒中患者在起病后24 h抽取肘静脉血,用酶联免疫吸附法测定MMP-9水平,同时用免疫比浊法测C反应蛋白(CRP)... 目的:研究血清基质金属蛋白酶-9(MMP-9)水平与缺血性卒中梗死体积和预后的关系,并探讨其潜在的机制。方法:对纳入研究的124例缺血性卒中患者在起病后24 h抽取肘静脉血,用酶联免疫吸附法测定MMP-9水平,同时用免疫比浊法测C反应蛋白(CRP)水平。根据卒中患者临床神经功能缺损程度评分标准在患者人院和出院时进行评分,所有患者均经CT或MRI确诊。结果:脑梗死组MMP-9、CRP、三酰甘油水平及白细胞计数均明显高于腔隙性梗死组和对照组,分别为(731.55±226.18):(622.64±196.72):(343.56±108.74)ng/ml,P<0.01;(8.65±3.77):(6.97±4.36):(3.85±1.28)mg/ml,P<0.01;(1.91±0.96):(1.52±O.85):(1.47±0.76)mmol/L,P<0.01;(9.17±1.99):(8.38±1.84):(8.25±1.72)×109/L,P<0.01。相关分析表明,MMP-9水平与CRP和白细胞计数呈直线正相关(r=0.224,P=0.013;r=0.289,P=0.001),与预后呈等级相关(r=0.180,P=0.046)。结论:脑梗死急性期血清MMP-9水平可能与梗死体积和近期预后密切相关。 展开更多
关键词 血清 基质金属蛋白酶-9 脑梗死 预后 临床标志物 梗死体积
下载PDF
血清单核细胞趋化蛋白1、基质金属蛋白酶9及胱抑素C水平对脑梗死患者预后的评估价值 被引量:6
4
作者 石小翠 胡美云 +1 位作者 杜寨 宋佳 《国际神经病学神经外科学杂志》 2021年第1期59-62,共4页
目的探究血清单核细胞趋化蛋白1(MCP-1)、基质金属蛋白酶9(MMP-9)及胱抑素C(Cys-C)水平对脑梗死患者预后的评估价值。方法回顾性分析2016年6月-2018年5月收治的173例脑梗死患者的临床资料,根据改良Rankin量表(mRS)评分结果将患者分为预... 目的探究血清单核细胞趋化蛋白1(MCP-1)、基质金属蛋白酶9(MMP-9)及胱抑素C(Cys-C)水平对脑梗死患者预后的评估价值。方法回顾性分析2016年6月-2018年5月收治的173例脑梗死患者的临床资料,根据改良Rankin量表(mRS)评分结果将患者分为预后良好组(MRS≤2分,98例)和预后不良组(MRS>2分,75例),比较两组患者的血清MCP-1、MMP-9、Cys-C水平及美国国立卫生研究院卒中量表(NIHSS)评分,分析MCP-1、MMP-9、Cys-C水平与患者NIHSS评分的相关性;绘制受试者工作特征(ROC)曲线,评估MCP-1、MMP-9及Cys-C对脑梗死患者预后的预测价值。结果预后不良组患者的血清MCP-1、MMP-9、Cys-C水平及NIHSS评分均高于预后良好组(P <0.05)。Pearson相关性分析结果显示,脑梗死患者的血清MCP-1、MMP-9、Cys-C水平与NIHSS评分均呈正相关(r=0.637、0.579、0.476,均P <0.05)。ROC曲线分析结果显示,MCP-1、MMP-9和Cys-C水平对脑梗死患者预后均有预测价值,其ROC曲线下面积(AUC)分别为0.846、0.764和0.688,对脑梗死患者预后的评估均具有统计学意义(P <0.001)。结论血清MCP-1、MMP-9和Cys-C水平均可对脑梗死患者的预后进行有效评估,可作为脑梗死患者预后的参考指标。 展开更多
关键词 脑梗死 预后 单核细胞趋化蛋白1 基质金属蛋白酶9 胱抑素C
下载PDF
高血压合并急性脑梗死患者血清MMP-9、RBP4水平与近远期预后的关系研究 被引量:5
5
作者 董兴龙 左雪梅 +3 位作者 宋国栋 敬乃鲁 王振国 王兴邦 《中国急救复苏与灾害医学杂志》 2022年第4期456-459,共4页
目的探究高血压合并急性脑梗死患者血清基质金属蛋白酶-9(MMP-9)、视黄醇结合蛋白4(RBP4)水平与近远期预后的关系。方法选取2019年2月—2020年9月兰陵县人民医院收治的108例高血压合并急性脑梗死患者。统计高血压合并急性脑梗死患者住院... 目的探究高血压合并急性脑梗死患者血清基质金属蛋白酶-9(MMP-9)、视黄醇结合蛋白4(RBP4)水平与近远期预后的关系。方法选取2019年2月—2020年9月兰陵县人民医院收治的108例高血压合并急性脑梗死患者。统计高血压合并急性脑梗死患者住院后2周及发病6个月后预后情况。对比近期预后不良组和预后良好组患者的临床资料。Logistic多因素回归分析影响高血压合并急性脑梗死患者近期预后的有关因素。对比远期预后不良组和远期预后良好组血清MMP-9、RBP4水平。制作受试者工作特征(ROC)曲线,以曲线下面积(AUC)评价血清MMP-9、RBP4对高血压合并急性脑梗死患者远期预后不良的预测价值。结果住院后2周、发病6个月后,高血压合并急性脑梗死患者预后不良发生率分别为44.44%、29.63%。近期预后不良组高血压分级Ⅲ级占比、空腹血糖(FPG)、糖化血红蛋白(HbA1c)、血清MMP-9及RBP4水平高于预后良好组(P<0.05),近期预后不良组尿酸(UA)水平则低于预后良好组(P<0.05)。Logistic回归分析结果显示,UA、血清MMP-9及RBP4均为高血压合并急性脑梗死患者近期预后的危险因素(OR=2.930、3.380、3.445,P<0.05)。远期预后不良组血清MMP-9、RBP4水平均高于远期预后良好组(P<0.05)。ROC分析显示,血清MMP-9、RBP4对高血压合并急性脑梗死患者远期预后进行预测的最佳截断点分别为401.25μg/L、181.71 mg/L,AUC分别为0.713、0.793。结论血清MMP-9、RBP4水平与高血压合并急性脑梗死患者近远期预后均相关,可作为对高血压合并急性脑梗死患者预后进行预测的重要参考指标。 展开更多
关键词 高血压 急性脑梗死 血清基质金属蛋白酶-9 视黄醇结合蛋白4 近远期预后
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部